558 related articles for article (PubMed ID: 32755579)
1. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
[TBL] [Abstract][Full Text] [Related]
4. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
5. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
6. Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage.
Kang HC; Lee YI; Shin JH; Andrabi SA; Chi Z; Gagné JP; Lee Y; Ko HS; Lee BD; Poirier GG; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2011 Aug; 108(34):14103-8. PubMed ID: 21825151
[TBL] [Abstract][Full Text] [Related]
7. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
8. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
10. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in
Li P; Zhen Y; Kim C; Liu Z; Hao J; Deng H; Deng H; Zhou M; Wang XD; Qin T; Yu Y
Sci Adv; 2023 Oct; 9(43):eadg7752. PubMed ID: 37878693
[TBL] [Abstract][Full Text] [Related]
11. Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.
Zhang N; Zhang Y; Qian H; Wu S; Cao L; Sun Y
Cell Death Differ; 2020 Sep; 27(9):2605-2619. PubMed ID: 32139900
[TBL] [Abstract][Full Text] [Related]
12. The E3 ubiquitin ligase thyroid hormone receptor-interacting protein 12 targets pancreas transcription factor 1a for proteasomal degradation.
Hanoun N; Fritsch S; Gayet O; Gigoux V; Cordelier P; Dusetti N; Torrisani J; Dufresne M
J Biol Chem; 2014 Dec; 289(51):35593-604. PubMed ID: 25355311
[TBL] [Abstract][Full Text] [Related]
13. Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.
Khan OM; Almagro J; Nelson JK; Horswell S; Encheva V; Keyan KS; Clurman BE; Snijders AP; Behrens A
Nat Commun; 2021 Apr; 12(1):2043. PubMed ID: 33824312
[TBL] [Abstract][Full Text] [Related]
14. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
15. Kaposi's sarcoma-associated herpesvirus processivity factor (PF-8) recruits cellular E3 ubiquitin ligase CHFR to promote PARP1 degradation and lytic replication.
Chung WC; Lee S; Kim Y; Seo JB; Song MJ
PLoS Pathog; 2021 Jan; 17(1):e1009261. PubMed ID: 33508027
[TBL] [Abstract][Full Text] [Related]
16. Clinical PARP inhibitors do not abrogate PARP1 exchange at DNA damage sites in vivo.
Shao Z; Lee BJ; Rouleau-Turcotte É; Langelier MF; Lin X; Estes VM; Pascal JM; Zha S
Nucleic Acids Res; 2020 Sep; 48(17):9694-9709. PubMed ID: 32890402
[TBL] [Abstract][Full Text] [Related]
17. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
[TBL] [Abstract][Full Text] [Related]
18. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
[TBL] [Abstract][Full Text] [Related]
19. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib.
Ding X; Zhu Z; Lapek J; McMillan EA; Zhang A; Chung CY; Dubbury S; Lapira J; Firdaus S; Kang X; Gao J; Oyer J; Chionis J; Rollins RA; Li L; Niessen S; Bagrodia S; Zhang L; VanArsdale T
Sci Rep; 2022 Jul; 12(1):12501. PubMed ID: 35864202
[TBL] [Abstract][Full Text] [Related]
20. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
